



May 1, 2019

Veracyte Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT) ("the Company") today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Veracyte intends to use the net proceeds from the offering for working capital and other general corporate purposes. The Company also intends to use a portion of the net proceeds to repay approximately \$12.4 million of its term loan. Veracyte may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies or other assets, although it has no present commitments or agreements to do so.

Morgan Stanley and SVB Leerink are acting as lead book-running managers for the offering, William Blair is acting as a book-running manager and BTIG and Janney Montgomery Scott are acting as co-managers.

The shares will be issued pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 1, 2019. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 01220, by email at syndicate@svbleerink.com or by telephone at (800) 808-7525, ext. 6132.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Veracyte, Afirma, Percepta, Envisia, Know by Design, the Veracyte logo and the Afirma logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190501006033/en/>

Source: Veracyte, Inc.

Investor and Media Contact:

Angie McCabe, (650) 243-6371

angie@veracyte.com